使用手持式眼底照相机和单张图像协议自动识别糖尿病视网膜病变的不同严重程度

IF 3.2 Q1 OPHTHALMOLOGY
Fernando K. Malerbi MD, PhD , Luis Filipe Nakayama MD , Gustavo Barreto Melo MD, PhD , José A. Stuchi MSC, PhD , Diego Lencione MSC , Paulo V. Prado MSC , Lucas Z. Ribeiro MD , Sergio A. Dib MD, PhD , Caio V. Regatieri MD, PhD
{"title":"使用手持式眼底照相机和单张图像协议自动识别糖尿病视网膜病变的不同严重程度","authors":"Fernando K. Malerbi MD, PhD ,&nbsp;Luis Filipe Nakayama MD ,&nbsp;Gustavo Barreto Melo MD, PhD ,&nbsp;José A. Stuchi MSC, PhD ,&nbsp;Diego Lencione MSC ,&nbsp;Paulo V. Prado MSC ,&nbsp;Lucas Z. Ribeiro MD ,&nbsp;Sergio A. Dib MD, PhD ,&nbsp;Caio V. Regatieri MD, PhD","doi":"10.1016/j.xops.2024.100481","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate the performance of artificial intelligence (AI) systems embedded in a mobile, handheld retinal camera, with a single retinal image protocol, in detecting both diabetic retinopathy (DR) and more-than-mild diabetic retinopathy (mtmDR).</p></div><div><h3>Design</h3><p>Multicenter cross-sectional diagnostic study, conducted at 3 diabetes care and eye care facilities.</p></div><div><h3>Participants</h3><p>A total of 327 individuals with diabetes mellitus (type 1 or type 2) underwent a retinal imaging protocol enabling expert reading and automated analysis.</p></div><div><h3>Methods</h3><p>Participants underwent fundus photographs using a portable retinal camera (Phelcom Eyer). The captured images were automatically analyzed by deep learning algorithms retinal alteration score (RAS) and diabetic retinopathy alteration score (DRAS), consisting of convolutional neural networks trained on EyePACS data sets and fine-tuned using data sets of portable device fundus images. The ground truth was the classification of DR corresponding to adjudicated expert reading, performed by 3 certified ophthalmologists.</p></div><div><h3>Main Outcome Measures</h3><p>Primary outcome measures included the sensitivity and specificity of the AI system in detecting DR and/or mtmDR using a single-field, macula-centered fundus photograph for each eye, compared with a rigorous clinical reference standard comprising the reading center grading of 2-field imaging protocol using the International Classification of Diabetic Retinopathy severity scale.</p></div><div><h3>Results</h3><p>Of 327 analyzed patients (mean age, 57.0 ± 16.8 years; mean diabetes duration, 16.3 ± 9.7 years), 307 completed the study protocol. Sensitivity and specificity of the AI system were high in detecting any DR with DRAS (sensitivity, 90.48% [95% confidence interval (CI), 84.99%–94.46%]; specificity, 90.65% [95% CI, 84.54%–94.93%]) and mtmDR with the combination of RAS and DRAS (sensitivity, 90.23% [95% CI, 83.87%–94.69%]; specificity, 85.06% [95% CI, 78.88%–90.00%]). The area under the receiver operating characteristic curve was 0.95 for any DR and 0.89 for mtmDR.</p></div><div><h3>Conclusions</h3><p>This study showed a high accuracy for the detection of DR in different levels of severity with a single retinal photo per eye in an all-in-one solution, composed of a portable retinal camera powered by AI. Such a strategy holds great potential for increasing coverage rates of screening programs, contributing to prevention of avoidable blindness.</p></div><div><h3>Financial Disclosure(s)</h3><p>F.K.M. is a medical consultant for Phelcom Technologies. J.A.S. is Chief Executive Officer and proprietary of Phelcom Technologies. D.L. is Chief Technology Officer and proprietary of Phelcom Technologies. P.V.P. is an employee at Phelcom Technologies.</p></div>","PeriodicalId":74363,"journal":{"name":"Ophthalmology science","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666914524000174/pdfft?md5=fbb1170100a68fa3c3edffca532778fd&pid=1-s2.0-S2666914524000174-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Automated Identification of Different Severity Levels of Diabetic Retinopathy Using a Handheld Fundus Camera and Single-Image Protocol\",\"authors\":\"Fernando K. Malerbi MD, PhD ,&nbsp;Luis Filipe Nakayama MD ,&nbsp;Gustavo Barreto Melo MD, PhD ,&nbsp;José A. Stuchi MSC, PhD ,&nbsp;Diego Lencione MSC ,&nbsp;Paulo V. Prado MSC ,&nbsp;Lucas Z. Ribeiro MD ,&nbsp;Sergio A. Dib MD, PhD ,&nbsp;Caio V. Regatieri MD, PhD\",\"doi\":\"10.1016/j.xops.2024.100481\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>To evaluate the performance of artificial intelligence (AI) systems embedded in a mobile, handheld retinal camera, with a single retinal image protocol, in detecting both diabetic retinopathy (DR) and more-than-mild diabetic retinopathy (mtmDR).</p></div><div><h3>Design</h3><p>Multicenter cross-sectional diagnostic study, conducted at 3 diabetes care and eye care facilities.</p></div><div><h3>Participants</h3><p>A total of 327 individuals with diabetes mellitus (type 1 or type 2) underwent a retinal imaging protocol enabling expert reading and automated analysis.</p></div><div><h3>Methods</h3><p>Participants underwent fundus photographs using a portable retinal camera (Phelcom Eyer). The captured images were automatically analyzed by deep learning algorithms retinal alteration score (RAS) and diabetic retinopathy alteration score (DRAS), consisting of convolutional neural networks trained on EyePACS data sets and fine-tuned using data sets of portable device fundus images. The ground truth was the classification of DR corresponding to adjudicated expert reading, performed by 3 certified ophthalmologists.</p></div><div><h3>Main Outcome Measures</h3><p>Primary outcome measures included the sensitivity and specificity of the AI system in detecting DR and/or mtmDR using a single-field, macula-centered fundus photograph for each eye, compared with a rigorous clinical reference standard comprising the reading center grading of 2-field imaging protocol using the International Classification of Diabetic Retinopathy severity scale.</p></div><div><h3>Results</h3><p>Of 327 analyzed patients (mean age, 57.0 ± 16.8 years; mean diabetes duration, 16.3 ± 9.7 years), 307 completed the study protocol. Sensitivity and specificity of the AI system were high in detecting any DR with DRAS (sensitivity, 90.48% [95% confidence interval (CI), 84.99%–94.46%]; specificity, 90.65% [95% CI, 84.54%–94.93%]) and mtmDR with the combination of RAS and DRAS (sensitivity, 90.23% [95% CI, 83.87%–94.69%]; specificity, 85.06% [95% CI, 78.88%–90.00%]). The area under the receiver operating characteristic curve was 0.95 for any DR and 0.89 for mtmDR.</p></div><div><h3>Conclusions</h3><p>This study showed a high accuracy for the detection of DR in different levels of severity with a single retinal photo per eye in an all-in-one solution, composed of a portable retinal camera powered by AI. Such a strategy holds great potential for increasing coverage rates of screening programs, contributing to prevention of avoidable blindness.</p></div><div><h3>Financial Disclosure(s)</h3><p>F.K.M. is a medical consultant for Phelcom Technologies. J.A.S. is Chief Executive Officer and proprietary of Phelcom Technologies. D.L. is Chief Technology Officer and proprietary of Phelcom Technologies. P.V.P. is an employee at Phelcom Technologies.</p></div>\",\"PeriodicalId\":74363,\"journal\":{\"name\":\"Ophthalmology science\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666914524000174/pdfft?md5=fbb1170100a68fa3c3edffca532778fd&pid=1-s2.0-S2666914524000174-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666914524000174\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666914524000174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的 评估嵌入在移动手持视网膜照相机中的人工智能(AI)系统在检测糖尿病视网膜病变(DR)和轻度以上糖尿病视网膜病变(mtmDR)方面的性能。方法参加者使用便携式视网膜照相机(Phelcom Eyer)拍摄眼底照片。采集的图像由深度学习算法视网膜改变评分(RAS)和糖尿病视网膜病变改变评分(DRAS)自动分析,深度学习算法由在 EyePACS 数据集上训练的卷积神经网络组成,并使用便携式设备眼底图像数据集进行了微调。主要结果指标主要结果指标包括人工智能系统在使用单视野、以黄斑为中心的眼底照片检测 DR 和/或 mtmDR 方面的灵敏度和特异性,并与严格的临床参考标准(包括阅片中心使用国际糖尿病视网膜病变严重程度分类表对双视野成像方案进行的分级)进行比较。结果 在分析的 327 名患者(平均年龄为 57.0 ± 16.8 岁;平均糖尿病病程为 16.3 ± 9.7 年)中,有 307 人完成了研究方案。使用 DRAS 检测任何 DR(灵敏度为 90.48% [95% 置信区间 (CI),84.99%-94.46%];特异度为 90.65% [95% CI,84.54%-94.93%])以及使用 RAS 和 DRAS 组合检测 mtmDR(灵敏度为 90.23% [95% CI,83.87%-94.69%];特异度为 85.06% [95% CI,78.88%-90.00%])时,人工智能系统的灵敏度和特异度都很高。结论这项研究表明,在由人工智能驱动的便携式视网膜相机组成的一体化解决方案中,每只眼睛只需拍摄一张视网膜照片,就能准确检测出不同严重程度的 DR。这种策略在提高筛查项目的覆盖率方面具有巨大潜力,有助于预防可避免的失明。财务披露F.K.M.是Phelcom Technologies公司的医疗顾问。J.A.S. 是 Phelcom Technologies 公司的首席执行官和专利权人。D.L.是 Phelcom Technologies 公司的首席技术官和专利权人。P.V.P. 是 Phelcom Technologies 的员工。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Automated Identification of Different Severity Levels of Diabetic Retinopathy Using a Handheld Fundus Camera and Single-Image Protocol

Purpose

To evaluate the performance of artificial intelligence (AI) systems embedded in a mobile, handheld retinal camera, with a single retinal image protocol, in detecting both diabetic retinopathy (DR) and more-than-mild diabetic retinopathy (mtmDR).

Design

Multicenter cross-sectional diagnostic study, conducted at 3 diabetes care and eye care facilities.

Participants

A total of 327 individuals with diabetes mellitus (type 1 or type 2) underwent a retinal imaging protocol enabling expert reading and automated analysis.

Methods

Participants underwent fundus photographs using a portable retinal camera (Phelcom Eyer). The captured images were automatically analyzed by deep learning algorithms retinal alteration score (RAS) and diabetic retinopathy alteration score (DRAS), consisting of convolutional neural networks trained on EyePACS data sets and fine-tuned using data sets of portable device fundus images. The ground truth was the classification of DR corresponding to adjudicated expert reading, performed by 3 certified ophthalmologists.

Main Outcome Measures

Primary outcome measures included the sensitivity and specificity of the AI system in detecting DR and/or mtmDR using a single-field, macula-centered fundus photograph for each eye, compared with a rigorous clinical reference standard comprising the reading center grading of 2-field imaging protocol using the International Classification of Diabetic Retinopathy severity scale.

Results

Of 327 analyzed patients (mean age, 57.0 ± 16.8 years; mean diabetes duration, 16.3 ± 9.7 years), 307 completed the study protocol. Sensitivity and specificity of the AI system were high in detecting any DR with DRAS (sensitivity, 90.48% [95% confidence interval (CI), 84.99%–94.46%]; specificity, 90.65% [95% CI, 84.54%–94.93%]) and mtmDR with the combination of RAS and DRAS (sensitivity, 90.23% [95% CI, 83.87%–94.69%]; specificity, 85.06% [95% CI, 78.88%–90.00%]). The area under the receiver operating characteristic curve was 0.95 for any DR and 0.89 for mtmDR.

Conclusions

This study showed a high accuracy for the detection of DR in different levels of severity with a single retinal photo per eye in an all-in-one solution, composed of a portable retinal camera powered by AI. Such a strategy holds great potential for increasing coverage rates of screening programs, contributing to prevention of avoidable blindness.

Financial Disclosure(s)

F.K.M. is a medical consultant for Phelcom Technologies. J.A.S. is Chief Executive Officer and proprietary of Phelcom Technologies. D.L. is Chief Technology Officer and proprietary of Phelcom Technologies. P.V.P. is an employee at Phelcom Technologies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Ophthalmology science
Ophthalmology science Ophthalmology
CiteScore
3.40
自引率
0.00%
发文量
0
审稿时长
89 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信